Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study

Nephrology Dialysis Transplantation

Volumn 30, Issue 9, 2015, Pages 1542-1551

  Fernandez Martin, Jose Luis ^a   Martinez Camblor, Pablo ^b,c   Dionisi, Maria Paula ^a   Floege, Jürgen ^d   Ketteler, Markus ^e   London, Gerard ^f   Locatelli, Francesco ^g   Gorriz, Jose Luis ^h   Rutkowski, Boleslaw ⁱ   Ferreira, Anibal ^j   Bos, Willem Jan ^k   Covic, Adrian ^l   Rodriguez Garcia, Minerva ^a   Sanchez, Jose Emilio ^a   Rodriguez Puyol, Diego ^m   Cannata Andia, Jorge B ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Oficina de Investigación Biosanitaria de Asturias   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e KLINIKUM COBURG   (Germany)

^f Centre Hospitalier FH Manhes   (France)

^g A MANZONI HOSPITAL   (Italy)

^h HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j NOVA MEDICAL SCHOOL   (Portugal)

^k ST ANTONIUS HOSPITAL   (Netherlands)

^l GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^m INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Calcium; chronic kidney disease; CKD MBD; cosmos; hemodialysis; phosphorous; PTH; survival

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE; BIOLOGICAL MARKER; PHOSPHORUS;

ADULT; ARTICLE; BONE METABOLISM; BONE MINERAL; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; BLOOD; BONE; CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; EUROPE; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE;

ADULT; BIOMARKERS; BONE AND BONES; CALCIUM; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

EID: 84940704357     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv099     Document Type: Article

References (46)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
2. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
3. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
4. K/DOQI clinical practice guiDelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1-201
5. KDIGO clinical practice guiDeline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone DisorDer (CKD-MBD). Kidney Int Suppl 2009; 113: S1-130
6. Hill AB. The Environment and Disease: Association or Causation Proc R Soc Med 1965; 58: 295-300
7. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J AmSoc Nephrol 2005; 16: 520-528
8. Kalantar-ZaDeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
9. Naves-Diaz M, Passlick-Deetjen J, GuinsburgAet al. Calcium, phosphorus, PTH and Death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 26: 1938-1947
10. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) GuiDeline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932
11. Phelan PJ,O'Kelly P,Walshe JJ et al. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. Ren Fail 2008; 30: 423-429
12. Fouque D, Roth H, Pelletier S et al. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets Nephrol Dial Transplant 2013; 28: 360-367
13. Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
14. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). AmJ Kidney Dis 2008; 52: 519-530
15. Cannata-Andia JB, FernanDez-Martin JL, Zoccali C et al. Current management of seconDary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol 2008; 21: 290-298
16. FernanDez-Martin JL, Carrero JJ, Benedik M et al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant 2013; 28: 1922-1935
17. Foley RN, Parfrey PS, Harnett JD et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16: 386-393
18. Jassal SV,Douglas JF, StoutRW. Prognosticmarkers in olDer patients starting renal replacement therapy. Nephrol Dial Transplant 1996; 11: 1052-1057
19. Leggat JE, Jr, Orzol SM, Hulbert-Shearon TE et al. Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis 1998; 32: 139-145
20. Ganesh SK, Stack AG, LevinNWet al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
21. Saran R, Bragg-Gresham JL, Rayner HCet al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 2003; 64: 254-262
22. Port FK, Pisoni RL, Bragg-Gresham JL et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004; 22: 175-180
23. Stevens LA, Djurdjev O, CarDew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: eviDence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779
24. Young EW, Akiba T, Albert JM et al. MagnituDe and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44(5 Suppl 2): 34-38
25. Menon V, Greene T, Pereira AA et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005; 46: 455-463
26. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46: 68-77
27. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793
28. Chang JJ, Concato J,Wells CK et al. Prognostic implications of clinical practice guiDelines among hemodialysis patients. Hemodial Int 2006; 10: 399-407
29. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of Death in inciDent dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357
30. Kimata N, Albert JM, Akiba T et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int 2007; 11: 340-348
31. Tentori F, Hunt WC, RohrscheibM et al. Which targets in clinical practice guiDelines are associated with improved survival in a large dialysis organization J Am Soc Nephrol 2007; 18: 2377-2384
32. Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for Decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916
33. Covic A, Kothawala P, Bernal M et al. Systematic review of the eviDence unDerlying the association between mineral metabolism disturbances and risk of all-causemortality, cardiovascularmortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523
34. Bradbury BD, Fissell RB, Albert JM et al. Predictors of early mortality among inciDent US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007; 2: 89-99
35. Noordzij M, Korevaar JC, Dekker FW et al. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guiDeline. Blood Purif 2008; 26: 231-237
36. Wald R, Sarnak MJ, Tighiouart H et al. DisorDered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008; 52: 531-540
37. Lacson E, Jr,WangW, Hakim RM et al. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis 2009; 53: 79-90
38. Robinson BM, Port FK. International hemodialysis patient outcomes comparisons revisited: the role of practice patterns and other factors. Clin J Am Soc Nephrol 2009; 4 Suppl 1: S12-S17
39. Larsson TE, Olauson H, HagstromE et al. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010; 30: 333-339
40. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of Death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127
41. BinDer H, Sauerbrei W, Royston P. Comparison between splines and fractional polynomials for multivariable moDel building with continuous covariates: a simulation study with continuous response. Stat Med 2013; 32: 2262-2277
42. Malloy EJ, Spiegelman D, Eisen EA. Comparing measures of moDel selection for penalized splines in Cox moDels. Comput Stat Data Anal 2009; 53: 2605-2616
43. GovinDarajulu US,Malloy EJ, Ganguli B et al. The comparison of alternative smoothing methods for fitting non-linear exposure-response relationships with Cox moDels in a simulation study. Int J Biostat 2009; 5: Article 2. doi: 10.2202/1557-4679.1104
44. Strasak AM, Umlauf N, Pfeiffer RM et al. Comparing penalized splines and fractional polynomials for flexible moDelling of the effects of continuous predictor variables. Comput Stat Data Anal 2011; 55: 1540-1551
45. Tentori F, Wang M, Bieber BA et al. Recent changes in therapeutic approaches and association with outcomes among patients with seconDary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol 2015; 10: 98-109
46. Torres A, Lorenzo V, HernanDez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: eviDence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442